Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus enzalutamide versus physician's choice (ARPI or docetaxel) in metastatic castration-resistant prostate cancer
2025-521327-67-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of inavolisib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Roche. Primary endpoint: Radiographic Progression-Free Survival (rPFS). Planned start Mar 2026; status: authorised.
02
Drugs
inavolisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-521327-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521327-67-00.